IPSEN – Buy-back programme – Art 5 of MAR – Week 31 – 2023
- 08 August 2023 - 1 mins read
Aggregated presentation by day and by market
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 31/07/2023 | FR0010259150 | 38 | 114.60 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 31/07/2023 | FR0010259150 | 71 | 114.41 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 31/07/2023 | FR0010259150 | 1,491 | 114.02 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/08/2023 | FR0010259150 | 39 | 115.90 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/08/2023 | FR0010259150 | 1,561 | 116.40 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/08/2023 | FR0010259150 | 44 | 114.20 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/08/2023 | FR0010259150 | 22 | 114.80 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/08/2023 | FR0010259150 | 1,534 | 114.57 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 03/08/2023 | FR0010259150 | 63 | 114.50 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 03/08/2023 | FR0010259150 | 213 | 114.42 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 03/08/2023 | FR0010259150 | 1,324 | 112.91 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/08/2023 | FR0010259150 | 139 | 115.05 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/08/2023 | FR0010259150 | 1,461 | 114.83 | XPAR |
| * Two-digit rounding after the decimal | TOTAL | 8,000 | 114.61 | |||
Attachment
11 July 2024
6 mins read
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
09 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024
1 mins read
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
08 July 2024
1 mins read
Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024
9 mins read
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
25 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
18 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
11 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
10 June 2024
12 mins read